In short
Farletuzumab Ecteribulin, also known as MORAb-202, is an innovative drug being studied in clinical trials for the treatment of various solid tumors. This antibody-drug conjugate targets folate receptor alpha (FRα) and is showing potential in treating cancers such as ovarian, endometrial, non-small cell lung, and triple-negative breast cancer. The ongoing trials aim to evaluate its safety, tolerability, and efficacy in patients with these challenging-to-treat cancers.
At a glance
- Drug Name
- Farletuzumab Ecteribulin (MORAb-202)
- Drug Type
- Antibody-drug conjugate targeting folate receptor alpha (FRα)
- Administration
- Intravenous infusion
- Target Cancers
- Solid tumors, including ovarian, endometrial, non-small cell lung, and triple-negative breast cancer
- Trial Phases
- Phase 1 and Phase 2
- Primary Objectives
- Evaluate safety, tolerability, determine recommended dose, assess preliminary efficacy
- Key Outcome Measures
- Objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS)
- Safety Monitoring
- Adverse events, laboratory values, vital signs, electrocardiograms, special focus on interstitial lung disease (ILD)
- Dosing Strategy
- Various schedules explored, typically every 3 weeks in 21-day cycles
What is Farletuzumab Ecteribulin?
Farletuzumab Ecteribulin, also known as MORAb-202, is an innovative drug being studied for the treatment of various solid tumors. It belongs to a class of medications called antibody-drug conjugates (ADCs), which are designed to target and kill cancer cells more precisely than traditional chemotherapy.
How Does It Work?
Farletuzumab Ecteribulin works by targeting a specific protein called folate receptor alpha (FRα) that is found on the surface of certain cancer cells. The drug consists of two main components:
- Farletuzumab: An antibody that specifically binds to FRα on cancer cells
- Ecteribulin: A potent anti-cancer drug that is attached to the antibody
When Farletuzumab Ecteribulin is administered, the antibody part seeks out and attaches to cancer cells expressing FRα. Once attached, the drug is absorbed by the cancer cell, releasing the ecteribulin component, which then kills the cell. This targeted approach aims to minimize damage to healthy cells and potentially reduce side effects compared to traditional chemotherapy.
What Conditions Does It Treat?
Farletuzumab Ecteribulin is being investigated for the treatment of several types of solid tumors, including:
- Ovarian cancer (OC): A type of cancer that begins in the ovaries
- Endometrial cancer (EC): Cancer that starts in the lining of the uterus
- Non-small cell lung carcinoma (NSCLC): The most common type of lung cancer
- Triple-negative breast cancer (TNBC): An aggressive form of breast cancer that lacks certain receptors
These cancers often express high levels of FRα, making them potential targets for Farletuzumab Ecteribulin therapy.
Clinical Trials and Research
Farletuzumab Ecteribulin is currently being studied in clinical trials to evaluate its safety, efficacy, and optimal dosing. Two main studies are underway:
- Phase 1 Study (NCT03386942): This study aims to determine the safety, tolerability, and maximum tolerated dose (MTD) of Farletuzumab Ecteribulin in patients with solid tumors.
- Phase 1/2 Study (NCT04300556): This larger study is evaluating the safety, tolerability, and efficacy of Farletuzumab Ecteribulin in patients with specific tumor types, including ovarian cancer, endometrial cancer, non-small cell lung cancer, and triple-negative breast cancer.
These trials are assessing various aspects of the drug's performance, including:
- Objective response rate (ORR): The percentage of patients whose tumors shrink or disappear after treatment
- Duration of response (DOR): How long the tumor response lasts
- Progression-free survival (PFS): The time from start of treatment until the cancer progresses or the patient dies
- Overall survival (OS): The time from start of treatment until death from any cause
Administration and Dosage
Farletuzumab Ecteribulin is administered as an intravenous (IV) infusion, typically once every 3 weeks in a 21-day cycle. The exact dosage and schedule may vary depending on the specific clinical trial and the patient's response to treatment. Some studies are also exploring different dosing regimens, such as weekly administration or the addition of oral corticosteroids to manage potential side effects.
Potential Side Effects
As with any cancer treatment, Farletuzumab Ecteribulin may cause side effects. The clinical trials are closely monitoring for adverse events, including:
- Interstitial lung disease (ILD): A group of lung disorders that can cause inflammation and scarring
- Hematological toxicities: Effects on blood cells, such as low white blood cell count (neutropenia) or low platelet count (thrombocytopenia)
- Infusion reactions: Allergic-like reactions that can occur during or shortly after receiving the drug
- Other general side effects such as fatigue, nausea, or changes in laboratory values
It's important to note that the full range of potential side effects is still being studied, and patients in clinical trials are closely monitored for any adverse reactions.
Future Prospects
The ongoing clinical trials will help determine the effectiveness and safety profile of Farletuzumab Ecteribulin. If the results are promising, this drug could potentially offer a new treatment option for patients with certain types of solid tumors, particularly those that have not responded well to other therapies.
Researchers are also investigating whether the levels of folate receptor alpha (FRα) in tumors can predict how well a patient might respond to Farletuzumab Ecteribulin. This could help identify which patients are most likely to benefit from this treatment in the future.